Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anamorelin to prevent weight loss in idiopathic pleuroparenchymal fibroelastosis patients awaiting lung transplantation
jRCTs031250402Recruiting
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of anamorelin in idiopathic pleuroparenchymal fibroelastosis (IPPFE). Primary endpoint: Change in body weight at Week 12. Started Apr 2026; status: recruiting.
02
Drugs
anamorelin
03
Conditions
idiopathic pleuroparenchymal fibroelastosis (IPPFE)
Beyond the preview
Go deeper on jRCTs031250402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031250402.